Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Tumor Lysis Syndrome 2Lymphoma 1Leukemia 1Inflammation 1Hyperuricemia 1Hematologic Neoplasms 1Gout 1Cardiovascular Diseases 1Arthritis 1

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 330Cisplatin 277Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 211Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Has results × Febuxostat × Clear all
NCT03605212 2021-06-03

FLORET

Menarini Group

Phase 1/2 Terminated
30 enrolled 14 charts
Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

NCT02500641 2019-06-21

FORWARD

Menarini International Operations Luxembourg SA

Phase 4 Completed
196 enrolled 9 charts

Arthritis, Cardiovascular Diseases, Gout, Inflammation, Hyperuricemia

NCT01724528 2014-11-03

FLORENCE

Menarini Group

Phase 3 Completed
346 enrolled 16 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Tumor Lysis Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡